Oct 29, 2025 8:30 am EDT Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025
Oct 17, 2025 7:30 am EDT Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation
Sep 22, 2025 8:30 am EDT Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD
Sep 11, 2025 5:01 pm EDT Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer
Sep 3, 2025 8:30 am EDT Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
Sep 2, 2025 8:30 am EDT Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Aug 7, 2025 7:30 am EDT Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
